Overview

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and pharmacokinetic characteristics after administration of HIP1503 and HGP1103 in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Treatments:
Solifenacin Succinate